In conclusion, our findings demonstrate that targeting the miR-22-3p/galectin-1 axis, which acts as a tumor suppressor and is associated with prognosis in breast cancer, may be a promising therapeutic strategy and may offer the possibility of tailoring treatment according to the molecular subtype of breast cancer. This evidence concerns the gene LGALS1 and breast cancer.